» Articles » PMID: 24714505

Outcomes of Pediatric Low-grade Gliomas Treated with Radiation Therapy: a Single-institution Study

Overview
Specialty Pediatrics
Date 2014 Apr 10
PMID 24714505
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation therapy is often considered the treatment of choice for low-grade gliomas. However, given the long-term effects of radiation on the developing brain, the appropriate use of radiation therapy in pediatric patients remains controversial. The purpose of this study was to evaluate progression-free survival (PFS) of pediatric low-grade glioma patients treated with radiation therapy. Data were obtained through a retrospective chart review of patients treated between 1991 and 2008 from a single tertiary care center in the midwest. The study population consisted of 17 patients, of whom 8 (47%) had tumor recurrence after radiation therapy. The median follow-up time was 8.2 years, with a range of 2.3 to 17.2 years. The median age at diagnosis was 5.4 years, and the median age at radiation therapy was 9.4 years. The 3- and the 10-year PFS were 69%± 11.7% and 46%± 13.3%, respectively. A significant difference in PFS was seen when comparing brainstem tumors with hypothalamic/optic pathway tumors (P=0.019). Differences in PFS based on the age at diagnosis, the extent of initial surgery, and indication for radiation therapy were not significant. A larger multicenter study is needed to better assess PFS in these patients.

Citing Articles

Case report: Pediatric low-grade gliomas: a fine balance between treatment options, timing of therapy, symptom management and quality of life.

Joh-Carnella N, Bauman G, Yock T, Zelcer S, Youkhanna S, Cacciotti C Front Oncol. 2024; 14:1366251.

PMID: 38912055 PMC: 11190070. DOI: 10.3389/fonc.2024.1366251.


Long-term outcomes of symptomatic optic pathway glioma: 32-year experience at a single Western Australian tertiary pediatric oncology center.

Rajagopal R, Khan M, Lethbridge R, Lee G, Lee S, Dyke J Front Oncol. 2023; 13:1157909.

PMID: 37519788 PMC: 10379632. DOI: 10.3389/fonc.2023.1157909.


Treatment of Pediatric Low-Grade Gliomas.

Farouk Sait S, Giantini-Larsen A, Tringale K, Souweidane M, Karajannis M Curr Neurol Neurosci Rep. 2023; 23(4):185-199.

PMID: 36881254 PMC: 10121885. DOI: 10.1007/s11910-023-01257-3.


Recent Updates on Radiation Therapy for Pediatric Optic Pathway Glioma.

Kim N, Lim D Brain Tumor Res Treat. 2022; 10(2):94-100.

PMID: 35545828 PMC: 9098980. DOI: 10.14791/btrt.2022.0003.


Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.

Tan J, Wijesinghe I, Kamarudin M, Parhar I Cancers (Basel). 2021; 13(4).

PMID: 33557011 PMC: 7913734. DOI: 10.3390/cancers13040607.


References
1.
Douw L, Klein M, Fagel S, van den Heuvel J, Taphoorn M, Aaronson N . Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009; 8(9):810-8. DOI: 10.1016/S1474-4422(09)70204-2. View

2.
Kim Y, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M . TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol. 2011; 64(10):850-2. DOI: 10.1136/jclinpath-2011-200133. View

3.
Mishra K, Squire S, Lamborn K, Banerjee A, Gupta N, Wara W . Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol. 2010; 100(1):121-7. PMC: 2951507. DOI: 10.1007/s11060-010-0151-7. View

4.
Heath J, Turner C, Poussaint T, Scott R, Goumnerova L, Kieran M . Chemotherapy for progressive low-grade gliomas in children older than ten years: the Dana-Farber experience. Pediatr Hematol Oncol. 2003; 20(7):497-504. DOI: 10.1080/08880010390232709. View

5.
Mishra K, Puri D, Missett B, Lamborn K, Prados M, Berger M . The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro Oncol. 2006; 8(2):166-74. PMC: 1871938. DOI: 10.1215/15228517-2005-011. View